Swiss National Bank trimmed its stake in shares of Edwards Lifesciences Corporation (NYSE:EW) by 0.1% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 775,198 shares of the medical research company’s stock after selling 700 shares during the period. Swiss National Bank owned 366,316.04% of Edwards Lifesciences Corporation worth $84,737,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently bought and sold shares of EW. Mn Services Vermogensbeheer B.V. lifted its holdings in Edwards Lifesciences Corporation by 513.9% during the second quarter. Mn Services Vermogensbeheer B.V. now owns 35,002 shares of the medical research company’s stock valued at $4,139,000 after purchasing an additional 29,300 shares in the last quarter. Ledyard National Bank lifted its holdings in Edwards Lifesciences Corporation by 2.4% during the second quarter. Ledyard National Bank now owns 50,556 shares of the medical research company’s stock valued at $5,978,000 after purchasing an additional 1,170 shares in the last quarter. Beese Fulmer Investment Management Inc. lifted its stake in shares of Edwards Lifesciences Corporation by 4.0% in the second quarter. Beese Fulmer Investment Management Inc. now owns 29,539 shares of the medical research company’s stock worth $3,493,000 after buying an additional 1,127 shares in the last quarter. Winslow Evans & Crocker Inc. lifted its stake in shares of Edwards Lifesciences Corporation by 2.9% in the second quarter. Winslow Evans & Crocker Inc. now owns 60,671 shares of the medical research company’s stock worth $7,114,000 after buying an additional 1,729 shares in the last quarter. Finally, B & T Capital Management DBA Alpha Capital Management lifted its stake in shares of Edwards Lifesciences Corporation by 2.5% in the second quarter. B & T Capital Management DBA Alpha Capital Management now owns 11,513 shares of the medical research company’s stock worth $1,361,000 after buying an additional 283 shares in the last quarter. 82.32% of the stock is currently owned by institutional investors and hedge funds.

In other news, CEO Michael A. Mussallem sold 32,900 shares of Edwards Lifesciences Corporation stock in a transaction on Monday, October 30th. The shares were sold at an average price of $100.93, for a total value of $3,320,597.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 5,300 shares of Edwards Lifesciences Corporation stock in a transaction on Monday, October 30th. The shares were sold at an average price of $101.12, for a total transaction of $535,936.00. The disclosure for this sale can be found here. Insiders sold a total of 138,580 shares of company stock worth $15,039,844 over the last ninety days. Corporate insiders own 2.13% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This story was posted by Daily Political and is the sole property of of Daily Political. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of US and international trademark and copyright law. The legal version of this story can be read at https://www.dailypolitical.com/2017/11/12/edwards-lifesciences-corporation-ew-holdings-cut-by-swiss-national-bank.html.

Shares of Edwards Lifesciences Corporation (EW) opened at $103.85 on Friday. The firm has a market cap of $21,976.74, a P/E ratio of 28.77, a PEG ratio of 1.86 and a beta of 0.46. The company has a current ratio of 3.49, a quick ratio of 2.76 and a debt-to-equity ratio of 0.33. Edwards Lifesciences Corporation has a 12-month low of $81.12 and a 12-month high of $121.45.

Edwards Lifesciences Corporation (NYSE:EW) last issued its quarterly earnings data on Tuesday, October 24th. The medical research company reported $0.84 earnings per share for the quarter, missing the consensus estimate of $0.86 by ($0.02). The company had revenue of $821.50 million for the quarter, compared to analysts’ expectations of $833.85 million. Edwards Lifesciences Corporation had a return on equity of 27.22% and a net margin of 22.47%. The firm’s quarterly revenue was up 11.1% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.68 EPS. research analysts expect that Edwards Lifesciences Corporation will post 3.75 earnings per share for the current fiscal year.

EW has been the topic of several research reports. BMO Capital Markets reissued a “buy” rating and issued a $132.00 price target on shares of Edwards Lifesciences Corporation in a research note on Friday, September 1st. William Blair reissued an “outperform” rating on shares of Edwards Lifesciences Corporation in a research note on Monday, August 28th. Barclays PLC raised their price target on shares of Edwards Lifesciences Corporation from $108.00 to $120.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 27th. Zacks Investment Research raised shares of Edwards Lifesciences Corporation from a “hold” rating to a “buy” rating and set a $130.00 price target on the stock in a research note on Tuesday, July 18th. Finally, Royal Bank Of Canada reissued a “buy” rating and issued a $130.00 price target on shares of Edwards Lifesciences Corporation in a research note on Friday, September 1st. Seven analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $125.17.

About Edwards Lifesciences Corporation

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Institutional Ownership by Quarter for Edwards Lifesciences Corporation (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.